Navigation Links
Repligen Announces Completion of Patient Enrollment in Phase 2b Clinical Trial of RG2417 for Bipolar Depression
Date:9/30/2010

ed changes in the size of our markets, our market share and product sales and other statements identified by words like "believe," "expect," "may," "will," "should," "seek," or "could" and similar expressions, constitute forward-looking statements. Such forward-looking statements are subject to a number of risks and uncertainties that could cause actual results to differ materially from those anticipated, including, without limitation, risks associated with: the success of our clinical trials; our ability to develop and commercialize products; our ability to obtain required regulatory approvals; the success of current and future collaborative relationships; the market acceptance of our products; our ability to compete with larger, better financed pharmaceutical and biotechnology companies; new approaches to the treatment of our targeted diseases; our expectation of incurring continued losses; our uncertainty of product revenues and profits; our ability to generate future revenues; our ability to raise additional capital to continue our drug development programs; our compliance with all Food and Drug Administration regulations; our ability to obtain; maintain and protect intellectual property rights for our products; the risk of litigation regarding our intellectual property rights; our limited sales and manufacturing capabilities; our dependence on third-party manufacturers and value added resellers; our ability to hire and retain skilled personnel; our volatile stock price; and other risks detailed in Repligen's annual report on Form 10-K on file with the Securities and Exchange Commission and the other reports that Repligen periodically files with the Securities and Exchange Commission. Actual results may differ materially from those Repligen contemplated by these forward-looking statements. These forward looking statements reflect management's current views and Repligen does not undertake to update any of these forward-looking statements to reflect a change in it
'/>"/>
SOURCE Repligen Corporation
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3 4 5

Related medicine technology :

1. Repligen to Present at the Rodman & Renshaw Annual Global Investment Conference
2. Repligen Announces Conference Call of First Quarter Fiscal Year 2011 Results
3. Repligen Reports Notice of Allowance of a United States Patent Covering the Use of Uridine to Treat the Symptoms of Bipolar Disorder
4. Repligen Receives Notice of Allowance for Recombinant Protein A Patent
5. Repligen Announces Long Term Supply Agreement with GE Healthcare for Recombinant Protein A
6. Repligen Reports Phase 3 Clinical Trial Results of RG1068 in Pancreatic Imaging
7. Repligen Announces Plans to Initiate a Phase 2b Trial for RG2417 in Bipolar Disorder
8. Repligen Receives FDA Fast Track Designation for RG1068 for Pancreatic Imaging
9. Repligen Initiates Phase 3 Clinical Trial of RG1068 for Pancreatic MRI Imaging
10. Repligen Reports Positive Phase 2a Clinical Trial Results of RG2417 for Symptoms of Bipolar Disorder
11. Warner Chilcott Announces the Closing of its $500 Million Senior Notes Offering
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:4/27/2015)... ALEXANDRIA, Va. and WASHINGTON ... of Specialty Pharmacy (NASP) and SmartBrief recently partnered to ... with a snapshot of the top news in the ... specialty pharmacies, pharmaceutical and biotechnology manufacturers, GPOs, distributors and ... free resource will launch on April 27, 2015. ...
(Date:4/27/2015)... -- The North America ... $4,211.2 million by 2019, at a CAGR of 5.0% from ... the North America ophthalmology surgery device ... It also provides a glimpse of the segmentation of this ... tables and figures. http://www.micromarketmonitor.com/market/north-america-ophthalmology-surgery-devices-9102894245.html ...
(Date:4/27/2015)... The North America ... and geography and includes analysis and forecast of revenue. This ... expected to reach $829.9 million by 2019, at a CAGR ... the TOC of the North America Optical microscopy market report, ... also provides a glimpse of the segmentation in this market, ...
Breaking Medicine Technology:NASP and SmartBrief Partner on Specialty Pharmacy SmartBrief 2North America Ophthalmology Surgery Device Market is Expected to Reach $4,211.2 Million by 2019, at a CAGR of 5.0% From 2014 to 2019 2North America Ophthalmology Surgery Device Market is Expected to Reach $4,211.2 Million by 2019, at a CAGR of 5.0% From 2014 to 2019 3North America Optical Microscopy Market is Expected to Reach $829.9 Million by 2019, at a CAGR of 3.0% From 2014 to 2019 2North America Optical Microscopy Market is Expected to Reach $829.9 Million by 2019, at a CAGR of 3.0% From 2014 to 2019 3
... Necessary For Diabetic Patients, BOSTON, Sept. 13 ... the United States alone. Coronary artery,disease (CAD) is a ... ischemia is common, and cardiac death or myocardial,infarction may ... the Detection of Ischemia in Asymptomatic Diabetics (DIAD),Study, presented ...
... Australia, Sept. 12 Sunshine Heart (ASX: SHC),a ... assist,technologies, today announced that it has received conditional ... U.S. Food and Drug,Administration (FDA) to begin its ... in patients with moderate heart failure. C-Pulse is,an ...
Cached Medicine Technology:Screening for Ischemia in Asymptomatic Patients With Type 2 Diabetes: Five- Year Outcomes in the DIAD Study 2Sunshine Heart Announces IDE Approval To Begin C-Pulse U.S. Clinical Feasibility Trial 2Sunshine Heart Announces IDE Approval To Begin C-Pulse U.S. Clinical Feasibility Trial 3
(Date:4/28/2015)... Colorado spine surgeon Donald Corenman, MD, ... popular spine education website NECKANDBACK.COM and his ... Media. This website has been redesigned to help patients ... spine, causes of neck and back pain, and conditions ... and personally answers questions in the neck and back ...
(Date:4/28/2015)... The buyer power score for ... indicating a medium level of buyer power in the ... equal power during negotiations. One factor helping buyer power ... health insurance policy from an insurance carrier (such as ... choose to self-fund their own policy or forgo insurance ...
(Date:4/28/2015)... It’s not all about the law at the Law ... litigation and plaintiff’s personal injury lawyer that has also served ... also about giving back to the community. This is ... Research Center Innovator’s Network. , “I believe there is a ... can and do good community-focused work in their communities,” said ...
(Date:4/28/2015)... SeniorCare.com has published the Misconception ... problem Americans have regarding aging and long-term care needs. ... services as they age, 63% of Americans do NOT ... the report, Carol Marak of SeniorCare.com interviewed 44 senior ... Care Association and The Scan Foundation. The experts discuss ...
(Date:4/28/2015)... Dead or damaged trees can quickly turn into ... cases, tree removal by a skilled team is recommended as ... , In their latest article , Precision Tree ... property owners today. Each method requires skill and expertise that ... , The article states that, “Tree removal is not “one ...
Breaking Medicine News(10 mins):Health News:Colorado Spine Surgeon Donald Corenman, MD, DC Launches Updated Version of NECKANDBACK.COM and Popular Back Pain Forum ASKSPINEDOC.COM 2Health News:Colorado Spine Surgeon Donald Corenman, MD, DC Launches Updated Version of NECKANDBACK.COM and Popular Back Pain Forum ASKSPINEDOC.COM 3Health News:New Data for Group Health Insurance Procurement Category Market Research Report from IBISWorld 2Health News:New Data for Group Health Insurance Procurement Category Market Research Report from IBISWorld 3Health News:New Data for Group Health Insurance Procurement Category Market Research Report from IBISWorld 4Health News:Seattle Attorney Paul Schneiderman Helping to Combat Cancer 2Health News:SeniorCare.com Report: America Has a Major Misconception on Aging 2Health News:Tree Removal Methods and Services Discussed in Recent Article by Precision Tree Services 2
... Jan. 28 Prime Companies, Inc. (Pink Sheets: PCIR) ... that will allow it to spin off its wholly ... 2007, to a San Diego firm which, once it ... 15 percent of the new company.The agreement with TransPacific ...
... Essential Hospital Guide to Get Your Loved One Out Alive," by ... Health Book of the Year by Allbooks Review Editor,s Choice Awards ... ... 2009 -- "Critical Conditions: The Essential Hospital Guide to Get Your ...
... of Health Strategies & Solutions, Inc the largest healthcare consultant in ... her expertise in management, governance, finance, operations and medical staff. ... ... The nation,s leading healthcare consulting firm, Health Strategies & ...
... A University of Rochester Medical Center study challenges common assumptions ... some people, surprisingly high levels remain in the body even ... suggests that BPA exposure may come from non-food sources, or ... journal Environmental Health Perspectives published the research online ...
... Jan. 27 Minnesotans with chronic,conditions and disabilities ... under the proposed budget of Gov. Tim Pawlenty, ... Center. , "As a ... thousands of Minnesotans following an illness, surgery or ...
... officials say company distributed ,adulterated, peanut butter products in ... -- The Georgia facility that produced the peanut butter ... in the past distributed questionable peanut butter product, U.S. ... 2008, Peanut Corporation of America, which owns the now-closed ...
Cached Medicine News:Health News:Prime Companies Reaches Agreement to Spin Off Subsidiary; Shareholders Gain 15 Percent Stake in New Telecommunications Company 2Health News:"Critical Conditions" Wins Best Health Book of the Year Awards 2Health News:New Employee of the Nations Largest Healthcare Consulting Firm 2Health News:Rochester study raises new questions about controversial plastics chemical 2Health News:Rochester study raises new questions about controversial plastics chemical 3Health News:Courage Center Experts Disagree With Gov. Pawlenty's Proposed Budget Cuts 2Health News:Courage Center Experts Disagree With Gov. Pawlenty's Proposed Budget Cuts 3Health News:Salmonella Outbreak Plant Shipped Dubious Product Before: U.S. Health Officials 2Health News:Salmonella Outbreak Plant Shipped Dubious Product Before: U.S. Health Officials 3
Assay for Determination of Initial Thrombin Formation...
Pefakit PiCT UFH Controls...
Pefakit PiCT LMWH Controls...
Pefakit PiCT LMWH Calibrators...
Medicine Products: